To explore the incidence and analyze the high risk factors of PIVH in premature infants in mainland China.
Introduction
Periventricular-intraventricular hemorrhage (PIVH) is a common disease in premature infants and one of the most important causes of mortality and disabilities, including cerebral palsy and neurodevelopmental delay, even in patients with milder grades of PIVH (1) (2) (3) . Although the incidence of PIVH has declined over the past two decades from 30-40% in the early 1980s to <20% in the 1990s in developed countries (4) (5) (6) (7) (8) , there is a lack of general data concerning PIVH in China, the largest developing country. The aims of the present study were to explore the incidence of PIVH and analyze its high risk factors in premature infants, and to suggest a working protocol for PIVH diagnosis, prevention and treatment in newborn infants at risk.
Materials and Methods

Patients
This study was a cohort prospective study involving 1122 premature infants (594 males; 528 females) delivered at <37 and >26 weeks of gestation at the Beijing Obstetrics & Gynecology Hospital and Qinhuangdao Maternity and Infants' Hospital from January 2002 to June 2005. Among all the newborn infants, the mean gestational age was 31.9±2.1 weeks and the mean birth weight was 1997±523 g.
Ultrasound criteria
Ultrasound examinations were carried out during the first week after birth. Intraventricular hemorrhage was diagnosed sonographically,based on the classification by Papile (9) as follows: Grade I, germinal matrix hemorrhage with no or minimal intraventricular hemorrhage; Grade II: intraventricular hemorrhage without ventricular dilatation; Grade III: intraventricular hemorrhage with primary ventricular dilatation; Grade IV: intraventricular hemorrhage and intraparenchymatous hemorrhage. Mild degrees of hemorrhage were defined as Grades I and II, while severe degrees of hemorrhage were defined as Grades III and IV.
Clinical data collection
The study recorded various kinds of perinatal data including maternal complications (pregnancy-induced hypertension, chronic hypertension, diabetes, anemia, etc.), premature rupture of fetal membranes, fetal distress, mode of delivery, gestational age, asphyxia, Apgar score, birth weight, sex, multiple birth, body temperature of ≤35.5°C, antenatal corticosteroid use, presence of respiratory distress and need for ventilatory treatment, anemia, blood pH≤7.20, SaO 2 <85%, PaCO 2 ≥7.33 kPa, serum osmolality, hyperlactacidemia and platelet parameters. Pregnant women at high risk for preterm birth at a gestational age of <35 weeks were randomly divided into two groups according to their in-patient registration numbers of theBeijing Military Region General Hospital. Pregnant women in the vitamin K 1 group received antenatal injections of vitamin K 1 at 10 mg/day intramuscularly or intravenously for 2 to 7 days. Women in the control group were not given vitamin K 1 injections. The women in the two groups had similar ages, domestic economic statuses, prenatal complications and routes of delivery. Besides, the infants were divided into phenobarbital and non-phenobarbital groups as well according to the in-patient registration number after birth. The infants in the phenobarbital group received an intravenous injection of phenobarbital at 20 mg/kg within 2 hours after birth, followed by injections at 5 mg/kg every 12 hours for 3 days. The infants in the non-phenobarbital group did not receive any phenobarbital injections after birth. And the study protocol was approved by the research committee of the Beijing Military Region General Hospital. To understand the blood count data, 50 healthy term infants without PIVH or any other diseases were selected as healthy controls. Their data were compared with the platelet parameters of the premature infants with PIVH to clarify whether abnormal platelet parameters have an influence on PIVH.
Statistical analysis
Data analyses were conducted with SPSS12.0 for Windows. Differences among the incidences of PIVH between the groups were assessed with χ 2 tests, one-way ANOVA or t-tests.
Results
Total incidence of PIVH in premature infants
The total incidence of PIVH in the study population was 55.2% (619/1122). Among the 619 cases, low degrees of PIVH accounted for 82.2% and severe degrees of PIVH accounted for 17.8%.
Correlation between gestational age and the incidence of PIVH
The incidences of PIVH were 78.5% (197/251) among infants at <32 gestational weeks, 57.1% (287/503) among infants at <32~35 gestational weeks and 36.7% (135/368) among infants at <35~37 gestational weeks. These data indicated that lower gestational ages were associated with higher incidences of PIVH. Among the 110 cases with severe PIVH, 79 were at <32 weeks, 27 at <35 weeks and only 4 at ≥35 weeks. These data indicated that lower gestational ages were associated with more severe degrees of PIVH.
Correlation between birthweight and the incidence of PIVH As shown in Table 1 , lower birthweights were associated with higher incidences of PIVH, and the incidences were especially high among infants with birthweights of <2000 g.
Correlation between mode of delivery and the incidence of PIVH
The incidences of PIVH were 52.7% in the cesarean section group and 57.2% in the vaginal delivery group. These data indicated that delivery mode was not associated with PIVH (χ 2 =1.15, p=0.283).
Correlation between multiple births and the incidence of PIVH
The incidences of PIVH were 57.4% in the multiple birth group and 54.8% in the single birth group. These data indicated that multiple births did not significantly increase the incidence of PIVH (χ 2 =0.11, p=0.740).
Correlation between use of antenatal corticosteroids and the incidence of PIVH Use of antenatal corticosteroids significantly reduced the incidence of PIVH in infants at <35 weeks, but had no marked influence on infants at ≥35 weeks ( Table 2) .
Effect of postnatal administration of phenobarbital on the incidence of PIVH
During the study, we examined the effect of postnatal administration of phenobarbital on the incidence of PIVH. Among 112 pre- Influence of maternal perinatal complications on the incidence of PIVH Maternal complications in the perinatal period significantly increased the incidence of PIVH among infants at <35 weeks, but not among infants at ≥35 weeks ( Table 3) .
Influence of fetal distress and birth asphyxia on the incidence of PIVH The incidences of PIVH were 67.4% and 49.0% in preterm infants with and without fetal distress and birth asphyxia, respectively (χ 2 =5.52, p=0.019).
Mechanical ventilation and the incidence of PIVH
Mechanical ventilation significantly increased the incidence of PIVH from 52.2% to 82.2% (χ 2 =13.79, p<0.001).
Hypoglycemia and the incidence of PIVH
The incidence of PIVH was much higher in infants with hypoglycemia than in infants without hypoglycemia (61.0% vs. 51.7%, χ 2 =5.99, p=0.014).
Serum osmolality and the incidence of PIVH
The serum osmolalities in the groups with and without PIVH were 292.7±9.77 and 293.9±8.83 mOsm/L, respectively, and showed no significant difference (t=1.01, p=0.335). Correlation between premature rupture of fetal membranes and the incidence of PIVH The incidences of PIVH were 60.2% and 49.9% in infants with and without premature rupture of fetal membranes, respectively (χ 2 =9.380, p=0.002).
Hypoxia, acidosis and hypercapnia and the incidence of PIVH
Hypothermia and the incidence of PIVH
Hypothermia (body temperature of ≤35.5°C) increased the incidence of PIVH in preterm infants from 54.1% to 65.1% (χ 2 =5.87, p=0.017).
Maternal antenatal administration of vitamin K 1 and the incidence of PIVH
Maternal antenatal administration of vitamin K 1 decreased the incidence of PIVH in preterm infants from 54.0% to 32.5% (χ 2 =4.16, p=0.041).
Correlations between platelet parameters and the incidence of PIVH The platelet parameters examined included platelet counts (PLT; ×10 9 /L), thrombocytocrit (PCT; %), mean platelet volume (MPV; fl) and platelet distribution width (MPV; %). These parameters were determined in 100 premature infants with PIVH, 60 premature infants without PIVH and 50 healthy term (Table 4) .
Discussion
The results of the present study indicate that the incidence of neonatal PIVH in China is much higher than previously reported incidences in developed countries (4) (5) (6) (7) (8) (9) (10) . The lower the birthweights, the higher is the incidence rate in PIVHs, especially for those infants with birthweights of <2000 g. This maybe mainly because the lower birthweight, the lower gestational ages the babies have, and accordingly the more premature in subependymal germinal matrix. Thus we think the screening cutoff point of a birth weight of 2000 g seems to be more adequate than 1500 g which was commonly used in China. PIVH in premature infants is an important cause of mortality and is associated with long-term morbidity including neurodevelopmental problems such as hydrocephalus, cerebral palsy, learning disabilities, language barrier, delayed mental development, severe behavioral problems and so on. Particularly in those infants with high grade hemorrhage, early onset PIVH is also likely to be severe and to progress to a higher grade. According to the results of this study, low gestational age, low birth weight, mechanical ventilation, hypoxia, acidosis, hypercapnia, hypothermia, hypoglycemia, hyperlactacidemia, maternal perinatal complications, fetal distress and birth asphyxia were the most important risk factors for PIVH. Premature rupture of fetal membranes (PROM) is also a common cause of PIVH which may be correlated with conditions of ascending intrauterine infection caused by PROM, and it is well known that inutero exposure to bacterial infection increases the incidence of PIVH in immature newborn infants (11) , and the inflammation and cytokines play an important role in the pathogenesis of brain damages (11, 12) . The more premature infants have a higher incidence, experiencing more severe PIVH, may be mainly because of low use of steroids, more premature in subependymal germinal matrix and Choroid Plexus Capillaries, etc. Serum osmolality, multiple births and cesarean section were not significantly correlated with the incidence of PIVH in premature infants. Maternal antenatal administration of vitamin K 1 or corticosteroids can significantly decrease the incidence of PIVH (13, 14) , and can be used routinely for women at risk of premature birth at <35 weeks of gestation. Antenatal supplementation with vitamin K 1 may significantly increase the plasma activities of factors II, VII and X, and consequently decrease the incidence of PIVH and lower the severity of hemorrhage. The immaturity of subependymal germinal matrix is the basic cause of PIVH in premature infants, when there is no intact basement membrane or only a basement-like material. Previous study showed use of antenatal corticosteroid can improve the maturation of subependymal germinal matrix (15) . Thus, the incidence and the degree of PIVH in preterm infants before 35 weeks gestational age can be decreased significantly. The present study also found that changes in platelet parameters, especially low platelet counts and a low thrombocytocrit, may be involved in the pathogenesis of PIVH in premature infants. It is important to monitor the changes in these platelet parameters in premature infants after birth. Postnatal administration of phenobarbital for the prevention of PIVH has been used for more than two decades, but its effects have remained controversial. A previous meta-analysis revealed no differences between a phenobarbital-treated group and a control group for PIVH incidence, severe PIVH, posthemorrhagic ventricular dilatation, severe neurodevelopmental impairment and death before hospital discharge (16) . Therefore, this strategy cannot be recommended as a prophylactic procedure for preventing PIVH in preterm infants and was found to be associated with an increased need for mechanical ventilation (16) . Our present results showed that, although the total incidence of PIVH did not differ between the phenobarbital-treated and control groups, phenobarbital administration appeared to be effective for decreasing the severity of PIVH in preterm infants delivered at <35 weeks of gestation. Hence, we believe that phenobarbital administration may still have some benefits for the prevention of PIVH in premature infants.
In conclusion, many high risk factors were involved in the incidence of PIVH in preterm infants. The incidence of PIVH in preterm infants in China was much higher than the previously reported incidences in developed countries, especially for infants with birthweights of <2000 g. Therefore, we suggest that a new cutoff point of 2000 g, rather than 1500 g, should be used in China to assess the risk of PIVH based on birthweight.
The present investigation provides a working protocol for PIVH diagnosis, prevention and treatment in premature newborn infants at risk. 
